---
title: "Piper Sandler Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295254717.md"
description: "Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Tectonic Therapeutic (TECX) with a $76 price target. Stifel Nicolaus also issued a Buy rating with a $75 target. Rahimi, a 5-star analyst in the Healthcare sector, has a 35.9% average return."
datetime: "2026-08-07T15:28:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295254717.md)
  - [en](https://longbridge.com/en/news/295254717.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295254717.md)
generator: "portal-rs"
---

# Piper Sandler Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Tectonic Therapeutic today and set a price target of $76.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Rahimi is a 5-star analyst with an average return of 35.9% and a 50.92% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Roivant Sciences, and aTyr Pharma.

In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $75.00 price target.

### Related Stocks

- [TECX.US](https://longbridge.com/en/quote/TECX.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [TD Cowen Keeps Their Buy Rating on Amgen (AMGN)](https://longbridge.com/en/news/298357051.md)
- [Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy](https://longbridge.com/en/news/298319347.md)
- [SEALSQ Reports H1 2026 Financial and Operational Results; Revenue Increases 131% to $11.2 Million; FY2026 Guidance Reaffirmed | LAES Stock News](https://longbridge.com/en/news/298739229.md)
- [Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104](https://longbridge.com/en/news/298369077.md)
- [06:19 ETIC Optimize Announces Odin and Joins the Cadence Connections Program](https://longbridge.com/en/news/298301349.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**